MarketPressRelease.com
Your Free Press Release Service And Distribution Network

Industry: Pharmaceutical

Pharmascroll, a Research & Consulting Firm, launches 30+ reports in MS & Migraine indications
Posted By: Pharmascroll Research and Consulting private Ltd | Posted On: February 21, 2018 2:04 am
Pharmascroll, a Market Research and Business Consulting firm, has come up with an extensive range of portfolio with the launch of over 30 reports in multiple indications

Anti CGRP molecules to make a paradigm shift in the Migraine treatment landscape
Posted By: Pharmascroll Research and Consulting Private Ltd | Posted On: February 20, 2018 8:49 am
All anti CGRP molecules have almost displayed similar efficacy & safety during trials. The products are expected to gain majority shares in the Migraine market given their superior efficacy and safety profiles as compared to the existing therapies.

Secondary Progressive MS - Majority MS patients progress to SPMS indicating huge market potential
Posted By: Pharmascroll Research and Consulting Private Ltd | Posted On: February 17, 2018 4:33 am
Nearly 50% of RRMS patients progress to SPMS in a 10 year time period indicating a huge market potential. However in present scenario, not many drugs are approved in the SPMS market indicating a huge unmet need.

Migraine - Launch of new molecules to further enhance treatment opportunities
Posted By: Pharmascroll | Posted On: February 12, 2018 6:11 pm
Launch of aCGRP molecules will shift momentum from Acute to preventive treatments. Migraine- Detailed overview provides Migraine overview, highlights Migraine epidemiology, mentions drugs in Migraine with sales & patient numbers forecasts.

Primary Progressive MS - Strong pipeline in progressive MS indicates paradigm shift in MS landscape
Posted By: Pharmascroll | Posted On: February 11, 2018 8:38 am
Many molecules are approved in RRMS, however, a strong pipeline in PPMS indicates a paradigm shift. PPMS- Detailed overview gives PPMS overview, highlights PPMS epidemiology, elaborates on PPMS drugs with the sales and patient numbers forecasts

Next»